Report Description Table of Contents Utilization Growth, Molecular Imaging Expansion, and Theranostics Reshape the PET-CT Scanner Device Market The Global PET-CT Scanner Device Market was valued at USD 2.80 billion in 2025 and is projected to reach USD 4.37 billion by 2032, expanding at a CAGR of 6.55% during 2026–2032, according to Strategic Market Research. PET-CT scanners are advanced molecular imaging systems that combine functional information from positron emission tomography (PET) with anatomical visualization from computed tomography (CT). PET uses radiotracers to identify abnormal metabolic activity, while CT provides detailed anatomical localization of disease, allowing physicians to determine both the biological behavior and physical location of abnormalities. The technology has become an essential component of oncology care, precision medicine, cardiology, neurology, and radiation therapy planning, with cancer diagnosis, staging, and treatment monitoring representing the largest clinical application areas. The PET-CT market is advancing from a scanner replacement market toward a broader precision imaging ecosystem supported by improved detector sensitivity, faster acquisition, artificial intelligence-based image reconstruction, wider scanning coverage, reduced radiation exposure, and advanced quantitative imaging capabilities. Leading companies including GE HealthCare, Siemens Healthineers, Philips, and United Imaging are developing next-generation PET-CT platforms that improve image quality, workflow efficiency, diagnostic accuracy, and integration with personalized treatment pathways. The commercial growth of PET-CT is increasingly being influenced by higher utilization of installed systems rather than only new scanner purchases. In the United States, hospitals and medical facilities perform more than 2.8 million PET-CT procedures annually, with PET procedure volumes increasing 12.2% in 2024 compared with the previous year, following a 10.2% increase in 2023. At the same time, the average number of scans performed per installed fixed PET/CT system increased by 8.2% in 2024, indicating that healthcare providers are absorbing additional demand through improved utilization of existing imaging infrastructure. This increase in utilization is creating demand for PET-CT systems that can support higher patient throughput, improved diagnostic confidence, and expanded clinical applications. Hospitals are increasingly evaluating PET-CT investments based on total workflow value, including detector performance, AI-enabled reconstruction, software capabilities, service support, upgrade pathways, and the ability to support emerging molecular imaging applications. PET-CT has become a major tool in global cancer care. In the United States, approximately 2,400–2,450 PET-CT sites perform around 2.0–2.2 million scans annually, with nearly 85% of PET scans used for cancer staging, treatment monitoring, and recurrence detection. Globally, approximately 5,800–6,200 PET scanners are in operation, with PET-CT representing the dominant technology configuration. Increasing cancer incidence, expanding radiotracer availability, replacement of aging systems, and wider adoption of molecular imaging are supporting continued investment in PET-CT infrastructure. Oncology remains the foundation of PET-CT demand, accounting for approximately 69% of PET imaging applications. The technology supports cancer staging, therapy-response assessment, recurrence detection, radiation therapy planning, and treatment monitoring throughout the patient journey. However, PET-CT utilization is expanding beyond traditional oncology through PSMA PET imaging for prostate cancer, cardiac PET applications, and neurological imaging such as amyloid PET, creating additional demand across multidisciplinary healthcare networks. The growing role of theranostics is further increasing the strategic importance of PET-CT within oncology workflows. PET imaging is increasingly used not only to diagnose disease but also to identify patients eligible for targeted radiopharmaceutical treatments and monitor treatment response. This transition is increasing demand for systems with accurate quantitative imaging, consistent image performance, and integration with advanced molecular imaging workflows. PET-CT adoption also depends on supporting healthcare infrastructure beyond the scanner itself. Facilities require reliable radiotracer supply, nuclear medicine specialists, trained technologists, radiation safety systems, image-processing capabilities, and maintenance support. Scanner economics are strongly influenced by institutional volume, with fixed PET/CT sites averaging 336 scans read annually per physician per site. Utilization varies significantly by facility size, ranging from 119 scans in hospitals with fewer than 200 beds to 567 scans in hospitals with more than 400 beds, highlighting the importance of referral networks, patient volumes, and operational efficiency in determining PET-CT investment returns. With global cancer cases expected to exceed 35 million annually by 2050, PET-CT adoption is expected to expand as healthcare systems focus on earlier diagnosis, treatment monitoring, personalized oncology, and molecularly targeted therapies. Future growth will depend not only on increasing scanner installations but also on improving utilization of existing systems, expanding access through mobile and shared imaging models, advancing AI-enabled workflows, and integrating PET-CT into broader precision medicine pathways. Overall, the PET-CT scanner market is transitioning from traditional diagnostic imaging equipment toward an integrated molecular imaging platform. The strongest opportunities will emerge from combining advanced detector technology, artificial intelligence, radiopharmaceutical innovation, service infrastructure, and clinical workflow integration to support more personalized disease detection and treatment planning. Product Architecture, Clinical Applications, Care Settings, and Regional Capacity Define the PET-CT Market Structure: Product Type: Stationary PET-CT scanners lead with 78.0% share and USD 2.18 billion in 2025 because high-volume hospitals and cancer centers require permanently available imaging capacity. Portable/mobile PET-CT scanners hold 22.0% share and USD 616 million, with their 7.8% CAGR supported by shared-service models and access expansion outside major imaging centers. Detector Type: Full-ring PET-CT scanners dominate with 72.0% share and USD 2.02 billion because complete detector coverage supports higher sensitivity, faster acquisition, and whole-body imaging. Partial-ring PET-CT scanners represent 28.0% share and USD 784 million, serving smaller facilities and cost-sensitive installations with lower acquisition requirements. Application: Oncology leads with 76.0% share and USD 2.13 billion because PET-CT is embedded in cancer staging, response assessment, recurrence detection, and treatment planning. Cardiology holds 11.0% share and USD 308 million through myocardial perfusion, viability, and inflammatory imaging. Neurology accounts for 9.0% share and USD 252 million, supported by metabolic brain imaging and the expanding clinical relevance of amyloid PET. Other applications represent 4.0% share and USD 112 million across infection, inflammation, research, and specialized molecular imaging. End User: Hospitals lead with 55.0% share and USD 1.54 billion because they consolidate nuclear medicine, oncology, radiology, neurology, and cardiology referrals. Diagnostic imaging centers hold 25.0% share and USD 700 million, with a 7.0% CAGR supported by outpatient imaging networks and outsourced diagnostic capacity. Academic and research institutions account for 10.0% share and USD 280 million through radiotracer research, kinetic imaging, and clinical studies. Ambulatory surgical centers represent 6.0% share and USD 168 million, with selective adoption connected to outpatient diagnostic workflows. Other facilities hold 4.0% share and USD 112 million, including specialist clinics, government centers, and shared-service providers. Modality: Hybrid PET-CT scanners dominate with 85.0% share and USD 2.38 billion because a single examination provides metabolic and anatomical information. Standalone PET scanners represent 8.0% share and USD 224 million, primarily serving legacy, research, and selected nuclear imaging requirements. Standalone CT scanners hold 7.0% share and USD 196 million within the defined modality analysis, supporting anatomical imaging and adjacent diagnostic workflows. Geography: North America leads with 42.0% share and USD 1.18 billion through established reimbursement, substantial procedure volumes, and mature radiopharmacy infrastructure. Europe represents 28.0% share and USD 784 million, supported by established nuclear medicine networks and continuing equipment modernization. Asia Pacific holds 21.0% share and USD 588 million and records the highest regional CAGR of 8.2% as hospitals expand molecular imaging capacity. Latin America accounts for 5.0% share and USD 140 million, with adoption concentrated in major hospitals and private imaging networks. The Middle East & Africa represent 4.0% share and USD 112 million, supported by selected public-sector and tertiary-care imaging projects. Fixed Infrastructure and Multi-Specialty Utilization Keep Stationary Systems Ahead Stationary PET-CT scanners led the product category with a 78.0% market share, valued at USD 2.18 billion in 2025, and are projected to expand at a CAGR of 6.2% during 2026–2032. Their leadership reflects the concentration of PET procedures in tertiary hospitals, comprehensive cancer centers, and high-volume diagnostic facilities. These institutions require permanent scanner availability to coordinate radiotracer delivery, patient preparation, image acquisition, interpretation, and treatment planning within a controlled clinical workflow. Fixed systems can also support several specialties on the same platform. Oncology departments use them for cancer staging and response assessment, while neurology and cardiology teams can schedule amyloid, metabolic brain, myocardial perfusion, or viability examinations. Products such as GE HealthCare’s Omni Legend and Siemens Healthineers’ Biograph systems offer digital detectors, automated workflows, and scalable configurations that help hospitals match scanner capability with procedure volume. Long equipment life, recurring software upgrades, and multi-year maintenance agreements further increase the revenue contribution of stationary systems. Full-Ring Detector Architecture Converts Sensitivity Into Throughput Full-ring PET-CT scanners dominated the detector category with a 72.0% share, representing USD 2.02 billion in 2025, and are expected to grow at a CAGR of 6.7% during 2026–2032. Complete detector coverage captures photon pairs from multiple directions around the patient, supporting the sensitivity and acquisition speed required for whole-body imaging. Higher sensitivity has direct operational value because it can support shorter examinations, improved small-lesion visualization, or lower administered radiotracer activity when appropriate protocols are used. Faster scans can help high-volume centers increase daily appointment capacity, although gains also depend on uptake-room availability, tracer delivery, staffing, and reporting efficiency. Digital full-ring systems from Siemens Healthineers, GE HealthCare, Philips, and United Imaging are increasingly favored during equipment replacement because they combine improved detector performance with motion correction, automated reconstruction, and quantitative imaging tools. Oncology Links Diagnosis, Response Assessment, and Theranostic Patient Selection Oncology represented the largest application segment with a 76.0% market share, accounting for USD 2.13 billion in 2025, and is projected to expand at a CAGR of 6.8% during 2026–2032. PET-CT is used at several points in cancer management, including initial staging, restaging, treatment-response evaluation, recurrence detection, radiotherapy planning, and patient selection for certain radioligand therapies. This creates repeat utilization throughout the patient pathway rather than limiting the scanner to a single diagnostic examination. The expanding radiotracer portfolio is strengthening oncology’s commercial position. FDG remains widely used across multiple cancers, while PSMA-targeted imaging has expanded PET-CT utilization in prostate cancer. Somatostatin-receptor imaging supports neuroendocrine tumor assessment and selection for radioligand therapy. Cancer centers developing theranostic programs require dependable imaging capacity for patient selection, treatment planning, and follow-up, which favors advanced stationary and full-ring systems with accurate quantification. Hospitals Capture the Broader Molecular Imaging Workflow Hospitals led the end-user category with a 55.0% market share, valued at USD 1.54 billion in 2025, and are projected to grow at a CAGR of 6.4% during 2026–2032. Hospitals can consolidate referrals from oncology, radiology, nuclear medicine, neurology, cardiology, and radiation oncology, giving them a larger and more diversified procedure base than most standalone facilities. Major hospitals are also better equipped to finance the infrastructure surrounding a PET-CT installation. This includes shielding, patient uptake rooms, radiopharmacy connections, radiation monitoring, specialist staffing, image-storage systems, and long-term maintenance. Integrated cancer programs can use the scanner for diagnosis, treatment planning, and follow-up within the same institution, improving scheduling coordination. Manufacturers such as GE HealthCare and Siemens Healthineers are well positioned in this setting because they combine scanner hardware with service, software, and broader hospital imaging portfolios. Hybrid Imaging Consolidates Metabolic and Anatomical Decision-Making Hybrid PET-CT scanners dominated the modality category with an 85.0% market share, valued at USD 2.38 billion in 2025, and are projected to expand at a CAGR of 6.7% during 2026–2032. Their leadership comes from providing metabolic and anatomical information during one examination. PET identifies abnormal biological activity, while CT shows its exact anatomical location, improving lesion characterization and clinical interpretation. The integrated approach also supports CT-based attenuation correction and reduces the registration uncertainty associated with examinations performed on separate scanners. In oncology, clinicians can determine whether metabolically active tissue corresponds to a tumor, lymph node, organ, or treatment-related change. Hospitals can select different CT configurations depending on whether the system will primarily support anatomical localization or more advanced diagnostic CT and treatment-planning functions. This flexibility makes hybrid PET-CT the standard commercial configuration for most clinical molecular imaging programs. North America Converts Procedure Volume Into Recurring Installed-Base Revenue North America held the largest regional position with a 42.0% market share, valued at USD 1.18 billion in 2025, and is expected to grow at a CAGR of 5.9% during 2026–2032. The region benefits from established oncology infrastructure, substantial PET procedure volumes, commercial radiopharmacy networks, specialist availability, and reimbursement for several clinically established indications. The United States also has a large installed base that generates recurring replacement, software, and service revenue. PET procedure volumes increased by 12.2% in 2024, while scans completed per installed fixed PET-CT system rose by 8.2%, indicating greater use of existing capacity. The wider adoption of PSMA imaging, cardiac PET, amyloid imaging, and theranostic services is adding procedure types beyond conventional FDG oncology. GE HealthCare, Siemens Healthineers, Philips, and United Imaging maintain active commercial portfolios in the region, supporting competition across system performance, service coverage, and ownership cost. Mobile Access Models Expand Capacity Beyond Permanent Installations Portable/mobile PET-CT scanners are projected to record the highest product-type CAGR of 7.8% during 2026–2032, rising from a 22.0% share and USD 616 million in 2025. Their faster growth reflects the need to provide molecular imaging at hospitals and diagnostic centers that do not have enough procedure volume or capital resources to support a permanently installed system. A mobile unit can serve several facilities on scheduled days, distributing acquisition and operating costs across a regional network. This model is particularly useful in rural areas, secondary cities, and smaller oncology centers where patients would otherwise travel to major tertiary hospitals. The segment nevertheless requires careful coordination because radiotracer delivery, scanner transport, radiation licensing, shielding, and patient scheduling must be aligned. Facilities with irregular referral volumes may therefore favor mobile access before committing to a fixed installation. Digital Full-Ring Platforms Lead the Detector Replacement Cycle Full-ring systems are expected to register the fastest detector-type CAGR of 6.7% during 2026–2032. The segment already accounted for 72.0% share and USD 2.02 billion in 2025, meaning its growth is supported by both new installations and the replacement of older detector platforms. Digital silicon photomultipliers, improved time-of-flight performance, wider detector coverage, and advanced reconstruction software make full-ring systems attractive to facilities seeking faster examinations and greater quantitative consistency. These capabilities are commercially valuable when they allow more patients to be scanned within existing operating hours or improve image quality without requiring higher radiotracer doses. The availability of scalable and upgradeable platforms can also reduce the risk of technological obsolescence during a scanner’s operating life. Radiotracer Expansion Extends Oncology Procedure Volumes Oncology is projected to record the highest application CAGR of 6.8% during 2026–2032, building on its 76.0% share and USD 2.13 billion valuation in 2025. The segment combines a large existing procedure base with new tracer-supported uses, making its growth broader than simple increases in cancer incidence. PSMA PET is reshaping prostate cancer imaging, while somatostatin-receptor imaging supports neuroendocrine tumor diagnosis and theranostic patient selection. PET-CT is also increasingly connected to radioligand-therapy programs, where imaging determines whether a patient expresses the relevant biological target and helps assess treatment response. These workflows favor scanners with reliable quantification, reproducible imaging, and capacity for repeat examinations. Outpatient Molecular Imaging Creates Selective ASC Growth Ambulatory surgical centers are projected to expand at the fastest end-user CAGR of 7.3% during 2026–2032, from a 6.0% share and USD 168 million in 2025. Their expansion is likely to remain concentrated in multidisciplinary outpatient campuses rather than conventional stand-alone surgical centers, as PET-CT requires specialized nuclear medicine infrastructure not normally present in routine ambulatory settings. Outpatient centers that combine oncology consultations, diagnostic imaging, biopsy, treatment planning, and selected procedures can use PET-CT to reduce referrals to separate hospital locations. The business case depends on sufficient specialist referrals, radiotracer access, reimbursement, and the ability to maintain equipment utilization. For this reason, ambulatory adoption will remain smaller than hospital utilization even though its percentage growth is faster. Hybrid Platforms Concentrate Modality Upgrades Hybrid PET-CT scanners are projected to record the highest modality CAGR of 6.7% during 2026–2032, following an 85.0% share and USD 2.38 billion valuation in 2025. Their growth reflects the continued replacement of less efficient standalone workflows and the clinical preference for co-registered metabolic and anatomical imaging. New hybrid platforms combine digital PET detectors with increasingly capable CT components, allowing institutions to select configurations according to clinical workload and budget. Oncology-focused facilities may prioritize sensitivity and quantitative accuracy, while multidisciplinary hospitals may select higher CT capability for cardiac imaging, diagnostic assessment, or radiotherapy planning. Software-based motion correction and automated reconstruction are further improving the consistency of hybrid examinations. Asia Pacific Converts Infrastructure Build-Out Into New Installations Asia Pacific is projected to register the highest regional CAGR of 8.2% during 2026–2032, increasing from a 21.0% share and USD 588 million in 2025. Expansion is supported by new cancer centers, tertiary-hospital development, private diagnostic networks, and investment in cyclotrons and radiopharmaceutical production across China, India, South Korea, and Southeast Asia. The region includes a large number of hospitals establishing molecular imaging services for the first time, creating revenue across scanners, site development, training, software, and maintenance. Domestic manufacturers such as United Imaging and Neusoft are also increasing price and technology competition. Adoption remains uneven outside major cities because PET-CT programs require trained personnel, dependable tracer delivery, and enough referral volume to cover operating costs. Suppliers that combine scalable systems with strong local service and implementation support are therefore likely to secure a greater share of new installations. Portfolio Breadth, Installed-Base Support, and Molecular Imaging Integration Define Competitive Leadership Based on PET-CT portfolio breadth, installed-base strength, service capabilities, regulatory progress, and participation across clinical molecular imaging, GE HealthCare and Siemens Healthineers are the two leading companies. GE HealthCare GE HealthCare holds a leading competitive position through its Omni Legend PET-CT portfolio, which offers multiple detector configurations for hospitals, cancer centers, and diagnostic imaging facilities with different procedure volumes. The platform combines digital detection, faster acquisition, lower-dose imaging options, and applications across oncology, cardiology, neurology, and theranostics. The company’s involvement in pharmaceutical diagnostics strengthens its position beyond scanner hardware. Products such as Vizamyl, Cerianna, and Flyrcado connect GE HealthCare with amyloid, breast cancer, and cardiac PET pathways. This combination of PET-CT equipment, radiotracers, workflow software, dosimetry tools, and service support gives the company access to a wider share of institutional molecular imaging expenditure. GE HealthCare’s disclosure of its largest-ever U.S. Omni Legend order in 2025 also indicates strong commercial traction. Siemens Healthineers Siemens Healthineers is another leading participant because its Biograph portfolio addresses routine imaging, high-volume clinical use, and advanced research. The FDA-cleared Biograph Trinion is designed for oncology, cardiology, neurology, and theranostic workflows, while Biograph Vision and Biograph Vision Quadra extend the portfolio into high-performance and long-axial-field imaging. Siemens differentiates its systems through time-of-flight performance, FlowMotion continuous-bed acquisition, motion-management applications, automated workflows, and scalable detector configurations. Its global service organization and established relationships with hospital radiology and nuclear medicine departments also reduce implementation and maintenance risk for healthcare providers. Other Companies Compete but Do Not Currently Hold the Same Leading Position: United Imaging Healthcare: United Imaging is a strong technology challenger with uMI Panorama, uMI 550, uMI Panvivo, and uEXPLORER, but its global service network and installed base remain less extensive than those of GE HealthCare and Siemens Healthineers. Philips: Philips remains an established competitor through the Vereos digital PET-CT system and its hospital imaging relationships, although its PET-CT portfolio is narrower than the multi-platform ranges of the two leading companies. Canon Medical Systems: Canon Medical offers the FDA-cleared Cartesion Prime and benefits from a broad diagnostic imaging portfolio, but it has lower visibility and a smaller commercial presence in PET-CT than the leading molecular imaging suppliers. Neusoft Medical Systems: Neusoft participates through competitively positioned PET-CT systems for hospitals and cost-sensitive procurement, but its reach is more concentrated in selected geographic and emerging markets. Precision Imaging, Theranostics, and Recurring Service Revenue Shape the Next PET-CT Growth Cycle The future growth of the PET-CT Scanner Market will extend beyond increasing scanner installations toward the development of integrated molecular imaging ecosystems that combine advanced hardware, artificial intelligence, radiopharmaceutical innovation, and precision oncology workflows. While mature markets will continue to generate demand through scanner replacement and technology upgrades, major growth opportunities will come from improving access, utilization, and clinical integration across emerging healthcare systems. A key commercial opportunity lies in the expansion of precision oncology and theranostics, where PET-CT is becoming essential for identifying suitable patients, guiding treatment decisions, and monitoring therapeutic response. The growing use of targeted radiotracers, including PSMA-based imaging for prostate cancer and other molecular targets, is increasing the clinical value of PET-CT beyond traditional diagnostic imaging. Companies that integrate high-sensitivity scanners with advanced software, quantitative biomarkers, and radiopharmaceutical partnerships will be positioned to capture greater value. Another major growth area is the development of AI-powered imaging platforms. Artificial intelligence can improve image reconstruction, automated lesion detection, workflow efficiency, reporting consistency, and treatment-response assessment. As healthcare providers face increasing imaging volumes and demand for faster diagnosis, AI-enabled PET-CT systems are expected to become an important factor in technology selection. The market also presents significant opportunities through expanded access models, including mobile PET-CT units, shared imaging networks, leasing models, and managed service solutions. These approaches can help overcome infrastructure limitations in smaller hospitals, secondary cities, and emerging markets where fixed installations may not be economically feasible. Growth in Asia Pacific, Latin America, and developing healthcare systems will depend on improving radiotracer supply chains, specialist availability, and reimbursement support. Beyond new equipment sales, the installed PET-CT base represents a long-term opportunity through software upgrades, detector improvements, maintenance contracts, and workflow optimization solutions. This shift is transforming the market from a hardware-focused business into a recurring-revenue imaging infrastructure model. Overall, the PET-CT market is evolving from a diagnostic imaging segment into a critical precision medicine platform. Future market leaders will be those that combine advanced detector technology, AI-driven analytics, radiopharmaceutical integration, and accessible deployment models to support the growing demand for personalized cancer care and molecular diagnostics PET-CT Scanner Device Market Report Coverage Table Report Attribute Details Forecast Period 2026 – 2032 Market Size Value in 2025 USD 2.80 Billion Revenue Forecast in 2032 USD 4.37 Billion Overall Growth Rate CAGR of 6.55% (2026 – 2032) Base Year for Estimation 2025 Historical Data 2019 – 2024 Unit USD Billion, CAGR (2026 – 2032) Segmentation By Product Type, By Detector Type, By Application, By End User, By Modality, By Geography By Product Type Stationary PET-CT Scanners, Portable/Mobile PET-CT Scanners By Detector Type Full-Ring PET-CT Scanners, Partial-Ring PET-CT Scanners By Application Oncology, Cardiology, Neurology, Other Applications By End User Hospitals, Diagnostic Imaging Centers, Academic and Research Institutions, Ambulatory Surgical Centers, Other Facilities By Modality Hybrid PET-CT Scanners, Standalone PET Scanners, Standalone CT Scanners By Region North America, Europe, Asia Pacific, Latin America, Middle East & Africa Country Scope U.S., Canada, UK, Germany, France, Italy, Spain, China, Japan, South Korea, India, Australia, Brazil, Mexico, Saudi Arabia, UAE, South Africa Market Drivers Increasing PET procedure utilization, expansion of oncology and theranostic workflows, wider use of PSMA, cardiac, and amyloid PET imaging, replacement of aging scanner platforms, adoption of AI-enabled reconstruction, growth of mobile and shared imaging models, and investment in radiotracer production infrastructure Customization Option Available upon request Frequently Asked Question About This Report Q1. What factors are driving the growth of the PET-CT scanner device market? A1. Growth is driven by increasing cancer incidence, rising PET imaging utilization, expansion of molecular imaging applications, radiopharmaceutical development, replacement of aging scanners, and growing adoption of precision oncology and theranostic workflows. AI-based reconstruction and improved detector technologies are also supporting higher diagnostic efficiency. Q2. Which application segment currently dominates the market? A2. Oncology is the leading application segment, accounting for 76.0% share and USD 2.13 billion in 2025. Its dominance is supported by extensive use of PET-CT for cancer staging, treatment-response monitoring, recurrence detection, radiation therapy planning, and molecularly guided treatment selection. Q3. Which product segment holds the largest market share? A3. Stationary PET-CT scanners lead the product segment with 78.0% share and USD 2.18 billion in 2025. Their leadership is supported by adoption in high-volume hospitals, cancer centers, and diagnostic facilities that require permanent imaging capacity and integration with nuclear medicine workflows. Q4. Which segment is expected to grow the fastest? A4. Portable/mobile PET-CT scanners are projected to be the fastest-growing product segment, expanding at a CAGR of 7.8% during 2026–2032. Growth is supported by shared imaging models, regional access expansion, and the need to provide molecular imaging services beyond major tertiary hospitals. Q5. Which region currently leads the market? A5. North America is the leading regional market, accounting for 42.0% share and USD 1.18 billion in 2025. The region benefits from advanced oncology infrastructure, established radiopharmacy networks, high PET procedure volumes, reimbursement support, and strong adoption of molecular imaging technologies. Q6. Which region is expected to record the fastest growth? A6. Asia Pacific is the fastest-growing regional market, projected to expand at a CAGR of 8.2% during 2026–2032. Growth is supported by expanding cancer-care infrastructure, increasing investment in nuclear medicine facilities, rising radiopharmaceutical availability, and adoption of advanced imaging technologies across China, India, Japan, and South Korea. Sources: Market Demand, Infrastructure, and Reimbursement IARC — Global Cancer Statistics and 2050 Projections IAEA IMAGINE — Global PET Scanner Availability CGS Medicare — PET Scan Coverage and Claim Submission Oncology and Theranostic Applications EANM — PET/CT Oncology Guidelines and Procedure Standards PubMed — Joint EANM/SNMMI PSMA PET/CT Guideline 2.0 FDA — Expanded Pluvicto Indication for PSMA-Positive Prostate Cancer Cardiac and Neurological Expansion FDA — Flyrcado Approval for Cardiac PET Imaging PubMed — Updated Appropriate-Use Criteria for Amyloid and Tau PET ASNC — Cardiac PET Guidelines and Clinical Resources PET-CT Technology and Competitive Platforms GE HealthCare — Omni Legend PET-CT Platform Siemens Healthineers — Biograph PET-CT Portfolio Philips — Vereos Digital PET-CT and United Imaging — uMI Panorama GS Table of Contents - Global PET-CT Scanner Device Market Report (2026–2032) Executive Summary Market Overview Market Attractiveness by Product Type, Detector Type, Application, End User, Modality, and Geography Strategic Insights from Key Executives (CXO Perspective) Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Summary of Market Segmentation by Product Type, Detector Type, Application, End User, Modality, and Geography Market Share Analysis Leading Players by Revenue and Market Share Market Share Analysis by Product Type, Detector Type, Application, End User, and Modality Investment Opportunities in the PET-CT Scanner Device Market Key Developments and Innovations Mergers, Acquisitions, and Strategic Partnerships High-Growth Segments for Investment Opportunities in Molecular Imaging Expansion, Theranostics, AI-Enabled Reconstruction, Mobile Imaging, Shared Imaging Networks, Radiopharmaceutical Integration, and Precision Oncology Market Introduction Definition and Scope of the Study Market Structure and Key Findings Overview of Top Investment Pockets Strategic Importance of PET-CT in Molecular Imaging, Oncology, Precision Medicine, Cardiology, Neurology, and Theranostic Workflows Research Methodology Research Process Overview Primary and Secondary Research Approaches Market Size Estimation and Forecasting Techniques Data Triangulation and Segment-Level Forecasting Approach Market Dynamics Key Market Drivers Challenges and Restraints Impacting Growth Emerging Opportunities for Stakeholders Impact of Radiopharmaceutical Supply, Reimbursement, Regulatory, and Infrastructure Factors Role of Molecular Imaging, Theranostics, AI-Enabled Reconstruction, and Quantitative Imaging in Market Expansion Utilization Growth, Scanner Replacement, Mobile Imaging, and Shared-Service Models in PET-CT Adoption Global PET-CT Scanner Device Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type: Stationary PET-CT Scanners Portable/Mobile PET-CT Scanners Market Analysis by Detector Type: Full-Ring PET-CT Scanners Partial-Ring PET-CT Scanners Market Analysis by Application: Oncology Cardiology Neurology Other Applications Market Analysis by End User: Hospitals Diagnostic Imaging Centers Academic and Research Institutions Ambulatory Surgical Centers Other Facilities Market Analysis by Modality: Hybrid PET-CT Scanners Standalone PET Scanners Standalone CT Scanners Market Analysis by Geography: North America Europe Asia Pacific Latin America Middle East & Africa Regional Market Analysis North America PET-CT Scanner Device Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Detector Type, Application, End User, and Modality Country-Level Breakdown: United States Canada Mexico Europe PET-CT Scanner Device Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Detector Type, Application, End User, and Modality Country-Level Breakdown: Germany United Kingdom France Italy Spain Rest of Europe Asia Pacific PET-CT Scanner Device Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Detector Type, Application, End User, and Modality Country-Level Breakdown: China India Japan South Korea Australia Rest of Asia Pacific Latin America PET-CT Scanner Device Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Detector Type, Application, End User, and Modality Country-Level Breakdown: Brazil Mexico Rest of Latin America Middle East & Africa PET-CT Scanner Device Market Analysis Historical Market Size and Volume (2019–2024) Base Year Market Size Analysis (2025) Market Size and Volume Forecasts (2026–2032) Market Analysis by Product Type, Detector Type, Application, End User, and Modality Country-Level Breakdown: Saudi Arabia United Arab Emirates South Africa Rest of Middle East & Africa Competitive Intelligence and Benchmarking Leading Key Players: GE HealthCare Siemens Healthineers Philips United Imaging Healthcare Canon Medical Systems Neusoft Medical Systems Mediso Ltd. MinFound Medical Systems Positron Corporation Fujifilm Holdings Corporation Shimadzu Corporation Carestream Health Competitive Landscape and Strategic Insights Benchmarking Based on Product Portfolio, Detector Performance, AI-Enabled Reconstruction, Workflow Integration, Service Coverage, Radiopharmaceutical Connectivity, and Regional Presence Installed-Base Strength and Replacement Cycle Analysis Molecular Imaging and Theranostic Positioning Precision Oncology and Advanced PET-CT Workflow Competitiveness Mobile, Shared-Service, Leasing, and Managed Imaging Strategy Analysis Recurring Software, Service, Maintenance, and Upgrade Revenue Analysis. Appendix Abbreviations and Terminologies Used in the Report References and Sources List of Tables Market Size by Product Type, Detector Type, Application, End User, Modality, and Geography (2026–2032) Regional Market Breakdown by Segment Type (2026–2032) Competitive Benchmarking of Leading PET-CT Scanner Device Vendors Radiopharmaceutical, Reimbursement, Infrastructure, and Procurement Risk Analysis Technology Adoption Trends Across Stationary PET-CT Scanners, Portable/Mobile PET-CT Scanners, Full-Ring PET-CT Scanners, Partial-Ring PET-CT Scanners, Hybrid PET-CT Scanners, Standalone PET Scanners, and Standalone CT Scanners List of Figures Market Drivers, Challenges, Opportunities, and Restraints Regional Market Snapshot (2025) Competitive Landscape by Market Share Growth Strategies Adopted by Key Players Market Share by Product Type, Detector Type, Application, End User, and Modality (2025 vs. 2032) Global PET-CT Scanner Device Ecosystem and Value Chain Analysis